Trials / Withdrawn
WithdrawnNCT01328106
Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
A Single-Arm, Open-Label, Multi-Center Study to Investigate the Objective Response Rate, Safety, and Pharmacokinetics of GSK1120212, a MEK Inhibitor, in Subjects With Metastatic Uveal Melanoma or With Mutation-Positive GNAQ or GNA11 Metastatic Melanoma
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether GSK1120212, a MEK inhibitor, is an effective and safe treatment for cancer subjects with metastatic uveal melanoma and mutation-positive GNAQ or GNA11 metastatic melanoma.
Conditions
- GNA11 Mutation-positive Metastatic Melanoma
- GNAQ Mutation-positive Metastatic Melanoma
- Cancer
- Metastatic Uveal Melanoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK1120212 | Repeating oral dose |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-08-01
- Completion
- 2012-05-01
- First posted
- 2011-04-04
- Last updated
- 2017-12-12
Source: ClinicalTrials.gov record NCT01328106. Inclusion in this directory is not an endorsement.